Skip to main content
Robert Giugliano, MD, Cardiology, Boston, MA

RobertPGiuglianoMD

Cardiology • Boston, MA

Preventive Cardiology, Cardiac Critical Care

Cardiovascular Medicine Brigham and Women's Hospital

Join to view full profile

Dr. Giugliano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Giugliano's full profile

Already have an account?

  • Office

    TIMI Study Office, Hale BTM Suite 7022, 60 Fenwood Road
    Brigham And Womens Hospital Cardiovascualar Division
    Boston, MA 02115
    Phone+1 617-278-0317
    Fax+1 617-264-5130

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Cardiovascular Disease, 1993 - 1996
  • Cedars-Sinai Medical Center
    Cedars-Sinai Medical CenterResidency, Internal Medicine, 1989 - 1993
  • Harvard Medical School
    Harvard Medical SchoolClass of 1989

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1990 - Present
  • MA State Medical License
    MA State Medical License 1993 - 2026

Awards, Honors, & Recognition

  • Fellow (FACC) American College of Cardiology

Publications & Presentations

PubMed

Journal Articles

  • Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction with Statins, Ezetimibe, and PCSK9 Inhibition  
    Robert P Giugliano, Marc S Sabatine, JAMA Cardiology
  • Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin Therapy  
    Prakash Deedwania, Narimon Honarpour, Marc S Sabatine, Robert P Giugliano, JAMA Cardiology
  • Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial Infarction  
    Christopher E Kurtz, Narimon Honarpour, Marc S Sabatine, Robert P Giugliano, JAMA Cardiology

Authored Content

  • Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
  • Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
  • Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
  • Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
  • The Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score, Cardiovascular Risk Stratification and a Strategy for Secondary Prevention with EzetimibeMay 2018
  • Oral Anticoagulation in Patients with Liver DiseaseMarch 2018
  • Clinical Events After Interruption of Anticoagulation in Patients with Atrial Fibrillation: An Analysis from the ENGAGE AF-TIMI 48 Trial☆February 2018
  • Clinical Events After Interruption of Anticoagulation in Patients with Atrial Fibrillation: An Analysis from the ENGAGE AF-TIMI 48 Trial☆February 2018
  • Join now to see all

Press Mentions

  • Association Between Changes in Serial Values of hsTn, Subsequent Cardiovascular Events
    Association Between Changes in Serial Values of hsTn, Subsequent Cardiovascular EventsJanuary 23rd, 2023
  • New Analysis Finds Broader Benefit for Post ACS Ezetimibe-Statin Combo
    New Analysis Finds Broader Benefit for Post ACS Ezetimibe-Statin ComboOctober 5th, 2021
  • Post-ACS Patients with Low LDL Levels Remain at Risk: IMPROVE-IT
    Post-ACS Patients with Low LDL Levels Remain at Risk: IMPROVE-ITOctober 4th, 2021
  • Join now to see all

Professional Memberships

Dr. Robert Giugliano, Dr. Robert Giugliano, MD, Dr. R Giugliano, Dr. Robert P Giugliano